Compare Danaher Corporation (DHR) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Taskus Inc — how do they compare? Danaher Corporation trades at $207.49 (market cap $147.18B), while Taskus Inc trades at $7.1 (market cap $650.52M). The key difference: Danaher Corporation is far larger — about 226.2× Taskus Inc's market cap, and Danaher Corporation pays a 0.76% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| DHR | TASK | |
|---|---|---|
Market Cap | $147.18B | $650.52M |
Sector | Health | Technology |
52-Week High | $242.05 | $18.21 |
52-Week Low | $161.91 | $4.57 |
Enterprise Value | $169.39B | $1.02B |
Dividend Yield | 0.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $204.76, up 2.37% today, near its pivot point of $203 with bullish technical signals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 expected at $1.92 EPS. Revenue for 2025 was $24.57B with a net income margin of 15.95%, though margins have trended down from 22.9% in 2022. Recent news includes the Masimo acquisition approval and a $172.5 million settlement over pandemic-era disclosures (Reuters, 2026-04-23).
Outlook is positive with strong analyst support (69% buy ratings) and a consensus price target of $202.33, slightly below current price. Risks include margin compression, high valuation (P/E 36.5), and integration challenges from acquisitions. Cash flow improved to $2.54B net in 2025 after a dip in 2023-2024, supporting dividend payments and growth initiatives.
TaskUs (TASK) trades at $7.30, down 6.65% today, but maintains strong fundamentals with Q2 2026 revenue beating guidance by $10.9 million. The stock shows bullish technical signals with support at $7 and bullish moving averages. Valuation metrics appear attractive with P/E of 6.29 and P/S of 0.55, while profitability remains solid with 8.75% net margin and 25.43% ROE. Recent CFO appointment and AI services growth provide positive catalysts.
The outlook remains positive with analyst consensus favoring Buy ratings (54.55%) and improving cash flow trends. Key opportunities include undervaluation relative to earnings power and AI services expansion. Risks include client concentration and potential earnings volatility. The combination of reasonable valuation and growth momentum supports a constructive view for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
